9 completed, 3 not yet recruiting, 2 recruiting, 2 terminated. 19 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 19 | Completed 9, Not yet recruiting 3, Recruiting 2, Terminated 2, Unknown 2, Suspended 1 |
| Phase 2 | 8 | Completed 3, Recruiting 2, Not yet recruiting 1, Suspended 1, Unknown 1 |
Follow Personality Disorders: new trials by email Literature Review of Personality Disorders trials Research Report on Personality Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder Psilocybin, Psilocybin-Assisted Therapy With Dialectical Behavior Therapy - Borderline Personality Disorder, Borderline Personality Pathology | Phase 1 | Not yet recruiting | University of Minnesota | 18 | 2026-12-01 | 2026-09-22 |
| Testing a Peer-led Trauma-focused Intervention for Significant Others of Those With BPD Trauma Recovery Program (official title TBD) - Posttraumatic Stress Disorder, Family Members | Phase 1 | Not yet recruiting | York University | 60 | 2026-10-01 | 2026-07-29 |
| Psilocybin for Treatment of OCD-2 Low Dose Psilocybin, High Dose Psilocybin - Obsessive - Compulsive Disorder | Phase 1 / Phase 2 | Not yet recruiting | Francisco A Moreno | 20 | 2026-09-08 | 2026-05-12 |
| A Pilot Trial of One-Day Accelerated TMS and D-cycloserine in Suicidal Patients With Borderline Personality Disorder TMS, D-Cycloserine (DCS) - Borderline Personality Disorder (BPD) | Phase 1 / Phase 2 | Recruiting | Mclean Hospital | 20 | 2026-06-10 | 2026-08-05 |
| A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder BI 3031185, Placebo - Borderline Personality Disorder, Attention Deficit Hyperactivity Disorder | Phase 1 | Completed | Boehringer Ingelheim | 78 | 2025-08-12 | 2026-08-10 |
| The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression., Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD, Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder. - Anxiety, Depression | Phase 1 | Completed | Rakitzi, Stavroula | 107 | 2025-06-02 | 2026-08-04 |
| Brain Signal Training to Enhance Affect Down-regulation Amygdala neurofeedback, Sham neurofeedback - Borderline Personality Disorder | Phase 1 / Phase 2 | Recruiting | Central Institute of Mental Health, Mannheim | 164 | 2025-04-23 | 2026-08-17 |
| Accelerated TMS in Psychosis repetitive Transcranial Magnetic Stimulation (rTMS) - Schizophrenia, Schizoaffective Disorder | Phase 1 / Phase 2 | Suspended | Beth Israel Deaconess Medical Center | 20 | 2022-11-29 | 2026-04-22 |
| Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU), Intranasal Placebo - Borderline Personality Disorder, BPD | Phase 1 | Terminated | Maria de las Mercedes Perez Rodriguez | 92 | 2013-09-01 | 2022-10-10 |
| Vasopressin Effects on Human Social Communication Vasopressin, Arginine, ADH, Placebo; Sterile Saline - Healthy | Phase 1 | Completed | Bowdoin College | 225 | 2011-09-01 | 2017-11-06 |
| Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents N-Acetylcysteine, fMRI - Deliberate Self Harm | Phase 1 | Completed | University of Minnesota | 67 | 2011-03-01 | 2019-05-01 |
| Creativity Group for Borderline Personality Disorder creativity group - Borderline Personality Disorder | Phase 1 | Completed | State University of New York - Upstate Medical University | 20 | 2011-02-01 | 2021-10-20 |
| 20 Weeks DBT Group Skills Training Study Skills Training - Borderline Personality Disorder | Phase 1 | Completed | Centre for Addiction and Mental Health | 84 | 2010-07-01 | 2016-05-27 |
| ENGAGE - Meeting Mental Health Needs of Complex Comorbid Patients Cognitive behavioural therapy, Standard treatment - Comorbidity, Substance Abuse | Phase 1 / Phase 2 | Unknown | University of Glasgow | 30 | 2009-11-01 | 2010-06-28 |
| Treating PTSD in Patients With Borderline Personality Disorder Dialectical Behavior Therapy, PTSD Protocol - Stress Disorders, Post-Traumatic, Borderline Personality Disorder | Phase 1 / Phase 2 | Completed | University of Washington | 39 | 2009-08-01 | 2015-11-23 |
| Evaluation of a Six-session Psycho-education Group Program psycho-education - Eating Disorders, Personality Disorders | Phase 1 | Terminated | Norwegian University of Science and Technology | 10 | 2006-11-01 | 2012-02-13 |
| Study of the Effect of Imagery Rehearsal Therapy (IRT) of Nightmares Imagery Rehearsal Therapy (IRT) - Nightmares, Anxiety Disorders | Phase 1 / Phase 2 | Completed | GGZ Centraal | 112 | 2006-02-01 | 2013-10-17 |
| Schizotypal Personality Disorder Risperidone Risperidone, Placebo - Schizotypal Personality Disorder | Phase 1 / Phase 2 | Completed | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 21 | 2003-01-01 | 2017-08-11 |
| Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder Crisis resolution - Borderline Personality Disorder, Post-Traumatic Stress Disorders | Phase 1 | Unknown | Laddis, Andreas, M.D. | 40 | 2006-02-20 |
Borderline Personality Disorder (11) · Stress Disorders, Post-Traumatic (4) · Psychotic Disorders (3) · Schizophrenia (3) · Schizotypal Personality Disorder (3) · Self-Injurious Behavior (3) · Anxiety Disorders (2) · Bipolar Disorder (2) · Depression (2) · Obsessive-Compulsive Disorder (2) · Antisocial Personality Disorder (1) · Attention Deficit Disorder with Hyperactivity (1) · Autism Spectrum Disorder (1) · Caregiver Burden (1)
Mental Disorders (19) · Behavior (6) · Behavioral Symptoms (6) · Stress Disorders, Traumatic (4) · Trauma and Stressor Related Disorders (4) · Schizophrenia Spectrum and Other Psychotic Disorders (3) · Bipolar and Related Disorders (2) · Mood Disorders (2) · Neurodevelopmental Disorders (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Anxiety Disorders (1) · Attention Deficit and Disruptive Behavior Disorders (1) · Chemically-Induced Disorders (1)
Dialectical Behavior Therapy (2) · Psilocybin (2) · Acetylcysteine (1) · Arginine (1) · Cognitive Behavioral Therapy (1) · Cycloserine (1) · Risperidone (1) · Transcranial Magnetic Stimulation (1) · Vasopressins (1)
University of Minnesota (2) · Beth Israel Deaconess Medical Center (1) · Boehringer Ingelheim (1) · Bowdoin College (1) · Central Institute of Mental Health, Mannheim (1) · Centre for Addiction and Mental Health (1) · Francisco A Moreno (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · GGZ Centraal (1) · Laddis, Andreas, M.D. (1) · Maria de las Mercedes Perez Rodriguez (1) · Mclean Hospital (1) · Norwegian University of Science and Technology (1) · Rakitzi, Stavroula (1) · State University of New York - Upstate Medical University (1)
United States (10) · Canada (2) · Germany (2) · Greece (1) · Netherlands (1) · Norway (1) · United Kingdom (1)
Andreas Laddis, MD (1) · Annette M. van Schagen, MA (1) · Are Holen, PhD MD (1) · Blake Bazel, M.S. (1) · Christian Paret-Voigt, Dr. (1) · Devin H Hanson, PhD, LP (1) · Dr. Polyxeni Georgila, M. D. (1) · Dr. Stavroula Rakitzi, PhD (1) · Francisco Moreno, MD (1) · Jaap Lancee, PhD (1) · Jan van den Bout, PhD (1) · Jenna M Traynor, PhD (1) · Joshua Brown, MD, PhD (1) · Kate M Davidson, PhD (1) · Kathryn R Cullen, MD (1)
PMID 33884617, PMID 20420716, PMID 20590434, PMID 22503959, PMID 23444147, PMID 24562087, PMID 26062135, PMID 26455674, PMID 29018407, PMID 29529508, PMID 31647267, PMID 32216138, PMID 40629288
R01MH087721 (1), R34MH082143 (1), UL1TR000067 (1)